|View printer-friendly version|
|November 04, 2015 8:00 a.m.|
|Teva to Present New Respiratory Data at the 2015 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology|
Data to be presented include a Phase III study examining the long-term effects of reslizumab on asthma-related quality of life (AQLQ) in asthma patients previously enrolled in reslizumab safety and efficacy studies. Reslizumab is an investigational humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of asthma in patients with elevated blood eosinophils who are inadequately controlled on an inhaled corticosteroid (ICS)-based regimen.
Additional data to be presented include a real-world analysis of symptom control, treatment satisfaction and quality of life measures in patients with perennial allergic rhinitis currently treated with QNASL® (beclomethasone dipropionate) Nasal Aerosol. A third abstract to be presented includes data evaluating the pharmacokinetic, pharmacodynamic and safety profiles of ProAir RespiClick® (albuterol sulfate) Inhalation Powder and ProAir® HFA (albuterol sulfate) Inhalation Aerosol in pediatric patients (ages 6-11) with asthma.
“Teva is committed to delivering and further developing therapies to
help meet the needs of the millions of people who suffer from
respiratory diseases,” said
The following data will be presented during poster sessions on
QNASL® (beclomethasone dipropionate) Nasal Aerosol
ProAir® RespiClick (albuterol sulfate) Inhalation Powder
Abstracts will be published in a supplement to the November issue of Annals
of Allergy, Asthma & Immunology and will also be available
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and allergic rhinitis. The Teva Respiratory portfolio is centered on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that address unmet needs. The company’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for inadequately controlled asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
Reslizumab is an investigational humanized monoclonal antibody developed
to target interleukin-5 (IL-5). IL-5 is a key cytokine shown to play a
crucial role in the maturation, activation and survival of eosinophils,
which are a type of white blood cell that are present at elevated levels
in the lungs, airways (sputum), and blood of many asthmatics. Evidence
shows that eosinophils play an active role in the pathogenesis of the
disease. Increased levels of eosinophils in the sputum and blood have
been shown to positively correlate with disease severity and increased
risk of asthma exacerbations. Reslizumab is thought to act by binding
circulating IL-5 and preventing IL-5 from interacting with its receptor.
Reslizumab has been submitted for and is currently under review by the
QNASL® (beclomethasone dipropionate) Nasal Aerosol is a prescription medication that treats seasonal and year-round nasal allergy symptoms in patients 4 years of age and older.
Important Safety Information
About ProAir® RespiClick
ProAir® RespiClick (albuterol sulfate) Inhalation Powder is indicated in patients 12 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Important Safety Information
Teva's Safe Harbor Statement under the
Teva Pharmaceutical Industries Ltd.